SRC and glioblastoma: Our findings suggest that these miR treatments reduce proliferative and migratory capabilities of LN299 and U87, in synergy with the antiproliferative effects of TMZ by downregulating Src/FAK, and Cyclin D1 pathways, subsequently leading to increased apoptosis in both GBM cell lines.